Medicare will now cover an AI-based test for prostate cancer that predicts which men will benefit from androgen deprivation therapy. The Centers for Medicare & Medicare Services approved the payment rate for ArteraAI as a clinical diagnostic test. The test improves risk stratification and personalizes treatment. It combines a patient’s clinical and pathologic information into an algorithm and analyzes prostate biopsies to estimate a patient’s risk of developing metastasis or dying from prostate cancer. The test is 80% accurate as a prognostic test and spares about two-thirds of men from the side effects of hormone therapy. It provides detailed, personalized information to help patients make confident decisions about prostate cancer treatment.
Source link
CMS Okays Payment for Novel AI Prostate Test
